Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 11/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347449 | 1.00 | NPC1 (0.38) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5406644 | 0.90 | NPC1 (0.39) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2896759 | 0.89 | GRM5 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1GRM5 | |
| SCHEMBL2896753 | 0.89 | GRM5 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1GRM5 | |
| SCHEMBL5432191 | 0.88 | KCNH2 (0.41) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5432422 | 0.86 | GRM2 (0.40) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5434436 | 0.85 | NPC1 (0.37) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5428088 | 0.83 | KDR (0.38) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5442838 | 0.81 | CYP11B2 (0.40) | NPC1RAB9AMDM2SMN1; SMN2TP53 | |
| SCHEMBL5399601 | 0.80 | CXCR1 (0.39) | NPC1RAB9AMDM2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | NPC1 705/4885RAB9A 943/4885MDM2 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.